Longer overall survival was achieved with TKIs targeting EGFR mutations in non-small cell lung cancer (NSCLC) patients.
Adult survivors of childhood cancer are at increased risk for late adverse pulmonary events.
Negative patient expectations are associated with an increased risk of adverse events in patients with breast cancer undergoing endocrine therapy.
Daratumumab plus lenalidomide and dexamethasone resulted in rapid, deep, durable responses in patients with multiple myeloma.
Estrogen receptor (ER)-positive breast cancers are often not a single tumor but a composite of related tumors, referred to as sub-clones.